Abstract
Small cell lung cancer (SCLC) is an aggressive cancer characterized by several autocrine growth mechanisms including stem cell factor and its receptor c-Kit. In order to arrive at potentially new and novel therapy for SCLC, we have investigated the effects of the tyrosine kinase inhibitor, STI 571, on SCLC cell lines. It has been previously reported that STI 571 does not only inhibit cellular Abl tyrosine kinase activity but also the PDGF receptor and c-Kit tyrosine kinases at similar concentrations (approximately 0.1 μM). There is no expression of the PDGF-receptor, and the Abl kinase is not activated by SCLC, but over 70% of SCLC contain the c-Kit receptor. Utilizing this preliminary data, we have determined that three (NCI-H69, NCI-H146 and NCI-H209) of five (including NCI-H82 and NCI-H249) SCLC cell lines had detectable c-Kit receptors and were inhibited in growth and viability at concentrations 1–5 μM of STI 571 after 48 h of treatment. The SCLC cell lines, NCI-H69, NCI-H146 and NCI-H209, showed a dose-response (tested between 0.1–10 μM) inhibition of tyrosine phosphorylation of c-Kit as well as in vitro kinase activity (at 5 μM) of c-Kit in response to STI 571. STI 571 inhibited cell motility, as assessed by time-lapsed video microscopy, within 6 h of STI 571 treatment (5 μM). STI 571 also decreased intracellular levels of reactive oxygen species (ROS) by at least 60%, at a concentration (5 μM) that also inhibited cell growth. Cell cycle analysis of STI 571 responsive cells showed that cells were generally slowed in G2/M phase, but there was no arrest at G1/S. A downstream phosphorylation target of c-Kit, Akt, was not phosphorylated in response to stem cell factor in the presence of STI 571. These data imply that STI 571 inhibits growth of SCLC cells through a mechanism that involves inactivation of the tyrosine kinase c-Kit. The effectiveness of STI 571 in this study suggests this drug may be useful in a clinical trial, for patients with SCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ and Lydon NB. . 1996 Cancer Res. 56: 100–104.
Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG and Druker BJ. . 1997 Blood 90: 4947–4952.
Chaudhry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R, Larson SM, Cuttitta F, Johnson BE and Mulshine JL. . 1999 Clin. Cancer Res. 5: 3385–3393.
Chute JP, Chen T, Feigal E, Simon R and Johnson BE. . 1999 J. Clin. Oncol. 17: 1794–1801.
DiPaola RS, Kuczynski WI, Onodera K, Ratajczak MZ, Hijiya N, Moore J and Gewirtz AM. . 1997 Cancer Gene Ther. 4: 176–182.
Druker BJ and Lydon NB. . 2000 J. Clin. Invest. 105: 3–7.
Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J and Sawyers C. . 1999 Blood 94: 368a.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB. . 1996 Nat. Med. 2: 561–566.
Ferry D, Hammond L, Ranson M, Kris M, Miller V, Murray P, Tullo A, Feyereislova A, Averbuch S and Rowinsky E. . 2000 Proc. ASCO. 19: 3a.
Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y and Takagi H. . 1991 Oncogene 6: 2291–2296.
Johnson BE and Kelley MJ. . 1995 Lung Cancer 12: S5–S16.
Krystal GW, Hines SJ and Organ CP. . 1996 Cancer Res. 56: 370–376.
Plummer HD, Catlett J, Leftwich J, Armstrong B, Carlson P, Huff T and Krystal G. . 1993 Cancer Res. 53: 4337–4342.
Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA, Ernst T, Sattler M, Chen LB and Griffin JD. . 1997 J. Clin. Invest. 100: 46–57.
Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD and Sugarbaker DJ. . 1999a Oncogene 18: 67–77.
Salgia R, Li JL, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, Sun Y, Pisick E, Hallek M, Ernst T, Tantravahi R, Chen LB and Griffin JD. . 1995 J. Biol. Chem. 270: 5039–5047.
Salgia R, Lin J, Narsimhan R, Chen W, Mach N, Dranoff G, Sattler M and Griffin J. . 1998 Blood 92: 487a.
Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, von Andrian UH, Chen LB, Gutierrez-Ramos JC, Pendergast AM and Griffin JD. . 1999b Blood 94: 4233–4246.
Sattler M and Salgia R. . 1997 Cytokine Growth Factor Rev. 8: 63–79.
Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV and Griffin JD. . 1997 J. Biol. Chem. 272: 10248–10253.
Sattler M, Verma S, Byrne CH, Shrikhande G, Winkler T, Algate PA, Rohrschneider LR and Griffin JD. . 1999a Mol. Cell. Biol. 19: 7473–7480.
Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R and Griffin JD. . 1999b Blood 93: 2928–2935.
Sawyers CL and Druker B. . 1999 Cancer. J. Sci. Am. 5: 63–69.
Acknowledgements
This work was supported by NIH grant CA75348-03 and Lowe's Center for Thoracic Oncology (R. Salgia), and Leukemia Research Foundation Fellowship (M. Sattler).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wang, WL., Healy, M., Sattler, M. et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19, 3521–3528 (2000). https://doi.org/10.1038/sj.onc.1203698
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203698
Keywords
This article is cited by
-
Imatinib modulates pro-inflammatory microenvironment with angiostatic effects in experimental lung carcinogenesis
Inflammopharmacology (2020)
-
PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor
Laboratory Investigation (2016)
-
Physalin A induces G2/M phase cell cycle arrest in human non-small cell lung cancer cells: involvement of the p38 MAPK/ROS pathway
Molecular and Cellular Biochemistry (2016)
-
New oncogenes drivers in lung cancer—new therapeutic targets
Current Pulmonology Reports (2016)
-
In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening
Molecular Diversity (2016)